⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqCM

LQDA

Liquidia Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

42.65USD

+2.9600 (+7.46%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on LQDA.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$0.98▼$1.1101
Next quarter-$0.28▼$1.2702
Current year$2.03▼$3.4802
Next year$2.19▼$5.5703

Recent quarters

Beat in 2 of the last 4

QuarterEstimateActualSurprise
2026-06-30$0.85$0.74-0.11 (-13.2%)
2026-03-31$0.4$0.52+0.12 (+29.2%)
2025-12-31$0.33$0.15-0.18 (-55.1%)
2025-09-30-$0.35-$0.04+0.31 (+88.7%)

Wall Street coverage

78 ratings from 11 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
HC Wainwright & Co.MaintainedBuy$58 $65Oct 15, 2026
LifeSci CapitalUpgraded from Market PerformOutperform$59Oct 14, 2026
Wells FargoMaintainedEqual-Weight$30 $33Oct 14, 2026
NeedhamMaintainedBuy$72 $58Oct 14, 2026
BTIGUpgraded from NeutralBuy$70Oct 14, 2026
Wells FargoDowngraded from OverweightEqual-Weight$108 $30Oct 2, 2026
HC Wainwright & Co.MaintainedBuy$130 $58Oct 2, 2026
Raymond JamesDowngraded from Strong BuyOutperform$106 $53Oct 1, 2026
BTIGDowngraded from BuyNeutral—Oct 1, 2026
NeedhamMaintainedBuy$110 $72Oct 1, 2026
Wells FargoMaintainedOverweight$62 $108Aug 13, 2026
B of A SecuritiesMaintainedNeutral$79 $92Aug 13, 2026
NeedhamMaintainedBuy$70 $110Aug 12, 2026
BTIGMaintainedBuy$109 $111Aug 12, 2026
LifeSci CapitalDowngraded from OutperformMarket Perform$90Aug 12, 2026
HC Wainwright & Co.MaintainedBuy$75 $130Jul 23, 2026
B of A SecuritiesDowngraded from BuyNeutral$64 $79Jun 29, 2026
BTIGMaintainedBuy$59 $109Jun 22, 2026
HC Wainwright & Co.MaintainedBuy$67 $75Jun 5, 2026
HC Wainwright & Co.MaintainedBuy$55 $67May 12, 2026
Wells FargoMaintainedOverweight$51 $62May 12, 2026
NeedhamMaintainedBuy$54 $70May 11, 2026
BTIGMaintainedBuy$50 $59May 11, 2026
ScotiabankInitiatedSector Outperform$30Oct 16, 2024
LifeSci CapitalInitiatedOutperform$30Oct 3, 2024

Insider transactions

204 filings from 28 insiders · 30 buy / 50 sell over 6m

Officers and directors of LQDA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
Schundler RussellOfficer, General CounselSell13.7k$28.48$390kOct 12, 2026
Saggar RajeevOfficer, Chief Medical OfficerSell9.2k$28.48$263kOct 12, 2026
Moomaw ScottOfficer, Chief Commercial OfficerSell8.9k$28.48$252kOct 12, 2026
Krepp SarahOfficer, Chief Human Resource OfficerSell5.2k$28.48$149kOct 12, 2026
Khindri SanjeevOfficer, Chief Development OfficerSell1.1k$28.48$31kOct 12, 2026
Kaseta MichaelOfficer, CFO and COOSell18.9k$28.48$539kOct 12, 2026
JEFFS ROGERDirector; Officer, Chief Executive OfficerSell32.7k$28.48$933kOct 12, 2026
Boyle DanaOfficer, Chief Accounting OfficerSell5.9k$28.48$168kOct 12, 2026
Adair JasonOfficer, Chief Business OfficerSell7.3k$28.48$208kOct 12, 2026
Schundler RussellOfficer, General CounselExercisePerformance Stock Units6.4k——Oct 9, 2026
Schundler RussellOfficer, General CounselExercisePerformance Stock Units3.8k——Oct 9, 2026
Schundler RussellOfficer, General CounselExercise6.4k——Oct 9, 2026
Schundler RussellOfficer, General CounselExercise3.8k——Oct 9, 2026
Saggar RajeevOfficer, Chief Medical OfficerExercisePerformance Stock Units4.5k——Oct 9, 2026
Saggar RajeevOfficer, Chief Medical OfficerExercisePerformance Stock Units3.5k——Oct 9, 2026
Saggar RajeevOfficer, Chief Medical OfficerExercise4.5k——Oct 9, 2026
Saggar RajeevOfficer, Chief Medical OfficerExercise3.5k——Oct 9, 2026
Moomaw ScottOfficer, Chief Commercial OfficerExercisePerformance Stock Units4.4k——Oct 9, 2026
Moomaw ScottOfficer, Chief Commercial OfficerExercisePerformance Stock Units3.1k——Oct 9, 2026
Moomaw ScottOfficer, Chief Commercial OfficerExercise4.4k——Oct 9, 2026

Analyst Notes

Sign in to write

No analyst notes on LQDA yet.

Analyst Ratings

8 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current24200Buy2.00
1 mo ago15200Buy2.13
2 mo ago15200Buy2.13
3 mo ago16100Buy2.00
Price target$54.38$33.00 – $70.00
+27.5% to target

Top voices on LQDA

Members whose judged calls on LQDA have played out most reliably.

No settled calls on LQDA yet. Nobody has filed a call with a deadline on it.

A member is listed once they have three judged calls on a name.

Sign in to make a call

A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.

A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.

A member’s prediction, judged on price history · not investment advice